



7-15
Pre. Audit. C
JUL 02 1992
GROUP 180
CEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this RESPONSE and the documents and disk referred to as enclosed therein are being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner of Patents and Trademarks, Box Sequence, Washington, D.C. 20231, Attn: M. Cashion, Supervisory Patent Examiner.

April C. Logan
April C. Logan, Reg. No. 33,950

June 19, 1992
Date of Deposit

Applicant: Cochrane, et al.)	
Serial No: 07/715,397)	Group Art Unit: 1811
Filed: June 14, 1991)	Examiner: S. Perkins
For: PULMONARY SURFACTANT PROTEIN)	Our Ref. No. SCR 0395P
AND RELATED POLYPEPTIDE)	San Diego, California
)	June 19, 1992

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES (37 CFR §1.821-1.825)

Box Sequence
Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Attn: Examiner Cashion

(C'attach.)

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under 37 CFR §1.821-1.825 mailed May 21, 1992, enclosed is a replacement copy of the Sequence Listing in ASCII computer readable form, submitted as required by 37 CFR §1.821(e), on which the Sequence Listing is labeled SCR0395S.APP.

I hereby state that the content of the paper submitted on April 13, 1992 in a Response to a Supplemental Office Action, paper number 6, mailed October 11, 1991 and the enclosed replacement computer readable copies of the Sequence Listing in ASCII format submitted in accordance with 37 CFR §1.821(a) through (c) and (e), respectively, are the same.

In the event that these corrections do not completely satisfy the requirements set forth in the enclosed Office Action, it is requested that this correspondence act as a conditional request for a petition to revive an unintentionally abandoned application under 37 CFR §1.137. In accordance with 37 CFR §1.137(b), in the event that this application is held to be abandoned for failure to satisfy the requirements of the Action, such an abandonment of the application was unintentional. Indeed, the submission of this correspondence and its enclosures is evidence of the intent to continue prosecution of the application. The present correspondence is being submitted as a proposed response to the outstanding Office Action and should be considered as such for purposes of 37 CFR §1.137(b).

In the event this application becomes unintentionally abandoned, the petition fee in the amount of \$1,050.00 should be charged to our Deposit Account No. 19-0962. Duplicate copies of this response are enclosed for accounting purposes.

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

Dated: 6/19/92

By April C. Logan
April C. Logan, Reg. No. 33,950
THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10666 N. Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(619) 554-2937